Another coronavirus vaccine trial in children to begin

4 May 2021
novavax_vaccine_large

Maryland, USA-based vaccine specialist Novavax (Nasdaq: NVAX) is to commence Phase III trials of its novel coronavirus vaccine candidate in children aged 12 to 17.

In a sign of the firm’s confidence in the product, the program comes ahead of any regulatory approvals having been secured for NVX-CoV2373, a vaccine which uses a traditional recombinant protein-based approach.

In January, the company released positive Phase III data which showed vaccine efficacy of 89.3% in trials conducted in the UK.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology